论文部分内容阅读
氨噻肟头孢菌素(Cefotaxime,商品名Daforn)是一个新的第3代头孢菌素,具有广谱、低毒、高效、耐酶等特点,1977年由前联邦德国Hoechst公司首先生产,该药对C~+及C~-菌具有强大抗菌活性,明显优于第1代及第2代头孢菌素,对某些耐药性菌株也极度敏感,是目前国际公认的优秀产品。1993年6月到8月我们应用东北制药总厂生产的氨噻肟头孢菌素治疗呼吸道感染病患者,并设对照组(头孢唑啉钠,即先锋霉素V号)比较,以观察其临床疗效,结果如下。
Cefotaxime (Daforn) is a new 3rd generation cephalosporin with broad spectrum, low toxicity, high efficiency and resistance to enzymes. It was first produced by Hoechst in the former Federal Republic of Germany in 1977, The drug has strong antibacterial activity against C ~ + and C ~ - bacteria, which is obviously superior to the first generation and second generation cephalosporins. It is also extremely sensitive to some resistant strains and is an internationally recognized excellent product. June 1993 to August we apply northeast pharmaceutical factory production cefotaxime cefotaxime treatment of respiratory tract infection patients, and the control group (cefazolin sodium, namely cephalosporin V) comparison to observe its clinical Efficacy, the results are as follows.